<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00210184</url>
  </required_header>
  <id_info>
    <org_study_id>IB2004-18</org_study_id>
    <secondary_id>CEPAFIRI</secondary_id>
    <nct_id>NCT00210184</nct_id>
  </id_info>
  <brief_title>Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years of Age and Older With Gastric Cancer</brief_title>
  <acronym>CEPAFIRI</acronym>
  <official_title>Multicentric Phase II Trial: Evaluation of Efficacy and Safety of FOLFIRI Association Treatment in Patients 70 Years Old and More Presenting Gastric Cancer Locally Advanced or Metastatic</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Bergonié</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi-Synthelabo</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut Bergonié</source>
  <brief_summary>
    <textblock>
      The number of patients over 70 years old with cancer is increasing in France. This population
      is heterogenous: physiological functions, presence of co-morbidities, and autonomy can vary a
      lot between subjects of the same age. Physicians hesitate to treat them with optimal doses
      because they are afraid of the risk of toxicity in spite of the benefits of treatment. Fifty
      eight percent of gastric cancers are diagnosed in patients over the age of 70 in France.
      FOLFIRI (irinotecan, leucovorin and fluorouracil) chemotherapy appears to be a promising
      treatment for digestive cancer. It increases the level of response and survival without major
      toxicity. It becomes necessary to evaluate patients, to propose adapted treatments for their
      conditions.

      The principal objectives are to demonstrate the efficacy of treatment, safety, survival and
      to find out if geriatric assessment data can help to better predict chemotherapy toxicity.
      The researchers plan to accrue 43 patients diagnosed with locally advanced or metastatic
      gastric cancer. They will receive FOLFIRI and 4 geriatric evaluations: before treatment, day
      1 cycle 2, day 1 cycle 4 and at the end of chemotherapy. These evaluations include tests of
      cognitive functions (MMS), nutritional status (MNA), co-morbidity (CIRS-G), mobility (Get up
      and Go), activities (ADL; IADL), quality of life (QLQ-C30), depression (GDS-15) and
      Lachs-Balducci screening.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date>July 2009</completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Partial response after 2 months of treatment</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric evaluation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Survival</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Gastric Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan associated to fluorouracil and leucovorin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  70 years of age or older

          -  Gastric cancer, locally advanced or metastatic

          -  No previous adjuvant treatment (surgery, radiotherapy, chemotherapy) in the last 6
             months

          -  One measurable lesion

          -  ECOG &lt; 3

          -  Biology and biochemistry within normal limits

          -  Life expectancy &gt; 12 weeks

        Exclusion Criteria:

          -  Other palliative chemotherapy for this cancer

          -  Other cancer in the last 5 years

          -  Previous treatment with irinotecan

          -  Atropine treatment not possible

          -  Concomitant cancer therapy except bone radiotherapy

          -  Metastases to brain or meninges with symptoms

          -  Other severe pathology uncontrolled

          -  Problem of compliance
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianne FONCK, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut Bergonié</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Bergonié - Centre Régional de Luttre Contre le Cancer de Bordeaux et du Sud Ouest</name>
      <address>
        <city>Bordeaux</city>
        <zip>33076</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Robert Boulin</name>
      <address>
        <city>Libourne</city>
        <zip>33700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Pau</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique Francheville</name>
      <address>
        <city>Perigueux</city>
        <zip>24000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire de Villeneuve sur Lot</name>
      <address>
        <city>Villeneuve sur Lot</city>
        <zip>47000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>December 29, 2011</last_update_submitted>
  <last_update_submitted_qc>December 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 2, 2012</last_update_posted>
  <keyword>Chemotherapy</keyword>
  <keyword>gastric cancer</keyword>
  <keyword>geriatric evaluation</keyword>
  <keyword>efficacy</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

